ES2147603T3 - Compuestos azaciclicos sustituidos por aralcoxi y aralquiltio. - Google Patents

Compuestos azaciclicos sustituidos por aralcoxi y aralquiltio.

Info

Publication number
ES2147603T3
ES2147603T3 ES95907110T ES95907110T ES2147603T3 ES 2147603 T3 ES2147603 T3 ES 2147603T3 ES 95907110 T ES95907110 T ES 95907110T ES 95907110 T ES95907110 T ES 95907110T ES 2147603 T3 ES2147603 T3 ES 2147603T3
Authority
ES
Spain
Prior art keywords
6alkyl
optionally substituted
substituted
nrarb
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95907110T
Other languages
English (en)
Inventor
Raymond Baker
Angus Murray Macleod
Eileen Mary Seward
Christopher John Swain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2147603T3 publication Critical patent/ES2147603T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I) EN DONDE N ES 1, 2 O 3 Y DONDE CUALQUIER ATOMO DE CARBONO DE (CH{SUB,2}){SUB,N} PUEDE SER SUSTITUIDO POR R{SUP,4} Y/O R{SUP,5}; X REPRESENTA O O S; R{SUP,1} REPRESENTA (CH{SUB,2}){SUB,Q}FENILO, EN DONDE Q ES 0, 1, 2 O 3, EL CUAL PUEDE SER OPCIONALMENTE SUSTITUIDO EN EL ANILLO DE FENILO; R{SUP,2} REPRESENTA ARILO SELECCIONADO A PARTIR DE FENILO Y NAFTILO; HETEROARILO SELECCIONADO A PARTIR DE INDAZOLILO, TIENILO, FURILO, PIRIDILO, TIAZOLILO, TETRAZOLILO Y QUINOLILO; BENZHIDRILO; O BENCILO; EN DONDE CADA MITAD DE ARILO O HETEROARILO PUEDE SER SUSTITUIDA; R{SUP,4} Y R{SUP,5} CADA UNO REPRESENTA INDEPENDIENTEMENTE H, HALO, C{SUB,1-6} ALQUILO, OXO, CO{SUB,2}R{SUP,A} O CONR{SUP,A}R{SUP,B}; R{SUP,6} REPRESENTA H O C{SUB,1-6}ALQUILO; R{SUP,7} REPRESENTA TRIFLUOMETILO, C{SUB,26} ALQUENILO, C{SUB,3-7} CICLOALQUILO, C{SUB,3-7}CICLOALQUIL C{SUB,1-4}ALQUILO, (CH{SUB,2}){SUB,P}NR{SUP,9}R{SUP,10}, CO{SUB,2}R{SUP,16}, CONR{SUP,9}R{SUP,10}, (CH{SUB,2}){SUB,P}CO{SUB,2}R{SUP,16}, (CH{SUB,2}){SUB,P}CONR{SUP,9}R{SUP,10}, (CH{SUB,2}){SUB,P}NR{SUP,9}COR{SUP,16}, (CH{SUB,2}){SUB,P}NHSO{SUB,2}R{SUP,11}, (CH{SUB,2}){SUB,P}OR{SUP,16}, (CH{SUB,2}){SUB,P}OC(O)R{SUP,9} O (CH{SUB,2}){SUB,P}OC{SUB,1-4}ALQUILCOR{SUP,17} O C{SUB,1-6} ALQUIL SUSTITUIDO POR UN GRUPO HIDROXI; R{SUP,8} REPRESENTA H, COR{SUP,A}, CO{SUB,2}R{SUP,A}, COCONR{SUP,A}R{SUP,B}, COCO{SUB,2}R{SUP,A}, C{SUB,3-7} CICLOALQUILO, C{SUB,37}CICLOALQUILC{SUB,1-4}ALQUILO, C{SUB,1-6} ALQUILO OPCIONALMENTE SUSTITUIDO POR UN GRUPO SELECCIONADO A PARTIR DE (CO{SUB,2}R{SUP,A}, CONR{SUP,A}R{SUP,B}, HIDROXI, CIANO, COR{SUP,A}, NR{SUP,A}R{SUP,B}, C(NOH)NR{SUP,A}R{SUP,B}, CONHFENIL(C{SUB,1-4}ALQUILO), COCO{SUB,2}R{SUP,A}, CONHNR{SUP,A}R{SUP,B}, C(S)NR{SUP,A}R{SUP,B}, CONR{SUP,A}C{SUB,16}ALQUILR{SUP,12}, CONR{SUP,13}C{SUB,2-6}ALQUINILO, CONR{SUP,13}C{SUB,2-6} ALQUENILO, COCONR{SUP,A}R{SUP,B}, CONR{SUP,A}C(NR{SUP,B})NR{SUP,A}R{SUP,B}, CONR{SUP,A} HETEROARILO, Y FENILO OPCIONALMENTE SUSTITUIDO O C{SUB,1-6} ALQUILO, OPCIONALMENTE SUSTITUIDO POR OXO, SUSTITUIDO POR UN HETEROCICLO AROMATICO OPCIONALMENTE SUSTITUIDO; R{SUP,A} Y R{SUP,B} REPRESENTAN CADA UNO INDEPENDIENTEMENTE H, C{SUB,1-6} ALQUILO, TRIFLUOMETILO O FENILO OPCIONALMENTE SUSTITUIDO POR C{SUB,1-6} ALQUILO, HALO O TRIFLUOMETILO. LOS COMPUESTOS SON DE USO PARTICULAR EN EL TRATAMIENTO DEL DOLOR, INFLAMACIONES, MIGRAÑAS Y EMESIS
ES95907110T 1994-02-11 1995-02-06 Compuestos azaciclicos sustituidos por aralcoxi y aralquiltio. Expired - Lifetime ES2147603T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9402688A GB9402688D0 (en) 1994-02-11 1994-02-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2147603T3 true ES2147603T3 (es) 2000-09-16

Family

ID=10750268

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95907110T Expired - Lifetime ES2147603T3 (es) 1994-02-11 1995-02-06 Compuestos azaciclicos sustituidos por aralcoxi y aralquiltio.

Country Status (10)

Country Link
US (1) US5665883A (es)
EP (1) EP0743939B1 (es)
JP (1) JPH09508901A (es)
AT (1) ATE192737T1 (es)
AU (1) AU685582B2 (es)
CA (1) CA2182734A1 (es)
DE (1) DE69516853T2 (es)
ES (1) ES2147603T3 (es)
GB (1) GB9402688D0 (es)
WO (1) WO1995021819A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780487A (en) * 1995-08-07 1998-07-14 Amer Moh Samir S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
DE19938736A1 (de) 1999-08-16 2001-02-22 Bayer Ag Verfahren zur Herstellung von [Bis-(trifluormethyl)-phenyl]-essigsäuren und deren Alkylestern sowie [Bis-(trifluormethyl)-phenyl]-malonsäure-dialkylester
DE60129562T2 (de) * 2000-06-12 2008-04-17 The University Of Rochester Methode zur Behandlung von Hitzewallungen durch Verwendung eines Tachykinin-Rezeptor-Antagonisten
EP1476149B1 (en) 2001-12-10 2008-08-06 Temple University of the Commonwealth System of Higher Education Substituted hydrazones as inhibitors of cyclooxygenase-2
US20060205724A1 (en) * 2002-05-29 2006-09-14 The Regents Of The University Of California Antagonizing nk-1 receptors inhibits consumption of substances of abuse
JP2004285038A (ja) * 2002-05-31 2004-10-14 Takeda Chem Ind Ltd ピペリジン誘導体、その製造法および用途
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GEP20125566B (en) 2005-07-15 2012-07-10 Amr Technology Inc Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
DK2606134T3 (da) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
WO2012026914A1 (en) * 2010-08-23 2012-03-01 Sam Amer & Co., Inc. Methods and compositions for treating internal and external hemorrhoids
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528495A1 (en) * 1991-08-20 1993-02-24 Merck Sharp & Dohme Ltd. Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
WO1994002461A1 (en) * 1992-07-28 1994-02-03 Merck Sharp & Dohme Limited Azacyclic compounds
WO1994019323A1 (en) * 1993-02-18 1994-09-01 Merck Sharp & Dohme Limited Azacyclic compounds, compositions containing them and their use as tachykinin antagonists

Also Published As

Publication number Publication date
JPH09508901A (ja) 1997-09-09
AU1544095A (en) 1995-08-29
DE69516853T2 (de) 2000-11-16
WO1995021819A1 (en) 1995-08-17
AU685582B2 (en) 1998-01-22
DE69516853D1 (de) 2000-06-15
EP0743939B1 (en) 2000-05-10
US5665883A (en) 1997-09-09
CA2182734A1 (en) 1995-08-17
GB9402688D0 (en) 1994-04-06
ATE192737T1 (de) 2000-05-15
EP0743939A1 (en) 1996-11-27

Similar Documents

Publication Publication Date Title
ES2147603T3 (es) Compuestos azaciclicos sustituidos por aralcoxi y aralquiltio.
ATE166867T1 (de) Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste
DK1244435T3 (da) Polyhydroxylerede, aromatiske forbindelser til behandling af amyloidose og alpha-synuclein fibril sygdomme
BRPI0412219A (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para regular a transdução de sinal método para tratamento ou prevenção de uma doença
DE69120430D1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE69729946D1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
DE69110561D1 (de) Mittel zur Behandlung und Vorbeugung von Bauchentzündungen, die als Wirkstoff Zink-L-Carnosin-Salze oder -Komplexe enthalten.
PT672042E (pt) Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
PT1107965E (pt) Eteres e tioeteres de piridilo como ligantes para receptores de acetilcolina nicotinica e as suas aplicacoes terapeuticas
EP0906307A4 (en) SUBSTITUTED IMIDAZOLES WITH CYTOKININ INHIBIRING EFFECT
DE69504300D1 (de) Gem-bissubstituierte azazyclische tachykinin-antagonisten
SE0104332D0 (sv) Therapeutic agents
NO992770L (no) Nye heterocyklisk substituerte benzamider og deres anvendelse ved bekjempelse av sykdommer
FI964772A (fi) (a)-annelloidut pyrrolijohdannaiset ja niiden käyttö farmasiassa
FI964771A0 (fi) (a)-annelloidut pyrrolijohdannaiset ja niiden käyttö farmasiassa
DK0790824T3 (da) 2,2-dichloralkancarboxylsyrer, fremgangsmåde til fremstilling deraf, lægemidler indeholdende disse og anvendelse af disse lægemidler til behandling af insulinresistens
ATE149488T1 (de) Hiv-protease inhibitoren, verwendbar für die behandlung von aids
HUP0303203A2 (hu) Eljárás demielinizáló betegségek vagy állapotok kezelésére
DE69617005D1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
RU98119076A (ru) Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2
DE69314911D1 (de) Cis-epoxide Derivate, verwendbar als irreversible HIV-Protease Inhibitoren und Verfahren und Zwischenprodukte zu ihrer Herstellung
ATE179168T1 (de) Substituierte spiroverbindungen zur behandlung von entzündungen
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
DE69630785D1 (de) Carbazole zur behandlung von mikrobiellen infektionen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 743939

Country of ref document: ES